These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 19196370)
1. Treating type 2 diabetes: how safe are current therapeutic agents? Philippe J; Raccah D Int J Clin Pract; 2009 Feb; 63(2):321-32. PubMed ID: 19196370 [TBL] [Abstract][Full Text] [Related]
2. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? Halimi S Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591 [TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint. Fisman EZ; Tenenbaum A; Motro M; Adler Y Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955 [TBL] [Abstract][Full Text] [Related]
4. [Clinically important effects of oral antidiabetic drug interactions]. Drzewoski J; Kopff B Pol Merkur Lekarski; 2000 Sep; 9(51):605-7. PubMed ID: 11126985 [TBL] [Abstract][Full Text] [Related]
8. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Pi-Sunyer FX Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064 [TBL] [Abstract][Full Text] [Related]
9. Beyond insulin replacement: addressing the additional needs of the diabetes patient. Dailey G Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():83-97. PubMed ID: 18577160 [TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones in type 2 diabetes--have they lived up to expectations? Bhansali A; Modi P J Indian Med Assoc; 2005 Jun; 103(6):343-6. PubMed ID: 16225162 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of diabetes mellitus with oral hypoglycemic agents]. Takamoto I; Kadowaki T Nihon Rinsho; 2011 Mar; 69(3):563-72. PubMed ID: 21400857 [TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Langley AK; Suffoletta TJ; Jennings HR Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515 [TBL] [Abstract][Full Text] [Related]
13. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. Malesker MA Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965 [TBL] [Abstract][Full Text] [Related]
14. [Thiazolidinediones--a new class of oral antidiabetics]. Schmitz OE; Brock B; Madsbad S; Beck-Nielsen H Ugeskr Laeger; 2001 Oct; 163(44):6106-11. PubMed ID: 11715152 [TBL] [Abstract][Full Text] [Related]
15. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Harrigan RA; Nathan MS; Beattie P Ann Emerg Med; 2001 Jul; 38(1):68-78. PubMed ID: 11423816 [TBL] [Abstract][Full Text] [Related]
16. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Campbell RK Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843 [TBL] [Abstract][Full Text] [Related]
18. [Metformin role in the treatment of type 2 diabetes in 2008]. Spada A; Philippe J Rev Med Suisse; 2008 Jun; 4(160):1392-4, 1396-7. PubMed ID: 18630062 [TBL] [Abstract][Full Text] [Related]
19. Glitazones in type 2 diabetes: an update. Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615 [TBL] [Abstract][Full Text] [Related]
20. Targeting the incretin system in type 2 diabetes mellitus. Potenza M; Rayfield EJ Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]